#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Astellas buys Xyphos Biosciences in $665 million deal

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | December 27, 2019
Astellas Pharma and Xyphos Biosciences announced that Astellas has acquired Xyphos.
Xyphos Biosciences
Acquisition   Xyphos Biosciences
With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology talent, to develop new and potentially better ways to mobilize, target and control immune cells to find, modulate and destroy targeted cells throughout the body.

Topics: Astellas Xyphos Biosciences

Considering the acquisition, $120 million was paid upon closing of the acquisition, and Xyphos became a wholly owned subsidiary of Astellas.

In addition to this payment and potential future development milestone payments, it will provide a total transaction value of $665 million.